In addition, CDK1 inhibitors could eliminate the effect of YOD1 overexpression (the proliferation and resistance to cisplatin), which further elucidates the tumor promoting mechanism of the YOD1-CDK1 axis. Here, YOD1 is linked to neoplasm.